Merck pulls diabetes-cholesterol drug in US due to low use
This article was originally published in Scrip
Executive Summary
Merck & Co. said it will stop selling Juvisync, a combination drug that treats diabetes and high cholesterol, because the treatment isn’t being used very much in the US.